British Medical Bulletin 46:368-382 (1990)
© 1990 The British Council
research-article |
Antiviral therapy: Hepatittis B
Department of Medicine and Hepatology, St Marys Hospital Medical School, Imperial College, University of London London
Abstract
Antiviral therapy for chronic hepatitis B virus infection can result in clearance of replicating virus from the liver and prevention of progression to cirrhosis in a substantial proportion of patients. Adenosine arabinoside monophophate, a potent inhibitor of HBV replication, is of limited usefulness because it causes significant neuromuscualr toxicity. Acyclovir alone is relatively non-toxic, but is clinically ineffective in eliminating HBV from the liver. Lymphoblastoid or recombinant alpha-intereferons are the best option at present and offer up to a 50% chance of long-term inhibition of HBV replication (with only minor side-effects) in patients who acquire the infection in adulthood. However alpha-interferon therapy alon is not effective whrn infection is acquired from birth. In this latter group of patients, prednisolone pre-treatment followed by alpha-interferon is currently under evaluation.